Antithrombotic drugs with adjuvant action against COVID-19

Antithrombotic drugs with adjuvant action against COVID-19

Waiting for the vaccine and/or the best antiviral treatment for coronavirus infection disease 2019 (COVID-19), after its outbreak in China at the beginning of 2020 and its viral diffusion around the world in the following weeks, several drugs have been suggested for their potential adjuvant support...

Full description

Bibliographic Details
Main Authors:	Pierpaolo Di Micco, Gianluca Di Micco, Vincenzo Russo, Andrea Fontanella
Format:	Article
Language:	English
Published:	PAGEPress Publications 2020-12-01
Series:	Italian Journal of Medicine
Subjects:	COVID-19 flavonoids heparin anticoagulants fondaparinux.
Online Access:	https://www.italjmed.org/index.php/ijm/article/view/1348

Similar Items

Rational Design of Anticoagulant Drugs Using Oligosaccharide Chemistry
by: Ahmed El Hadri, et al.
Published: (2011-02-01)

Blood Targets of Adjuvant Drugs Against COVID19
by: Di Micco P, et al.
Published: (2020-07-01)

Heparin and SARS-CoV-2: Multiple Pathophysiological Links
by: Pierpaolo Di Micco, et al.
Published: (2021-12-01)

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland
by: Lorenzo A. Alberio, et al.
Published: (2020-04-01)

Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV)
by: Giuseppe Camporese, et al.
Published: (2023-06-01)

Antitrombóticos nas síndromes coronarianas agudas: diretrizes atuais e novas evidências Antithrombotics in acute coronary syndromes: actual guidelines and new evidences
by: Luiz Eduardo Fonteles Ritt, et al.
Published: (2008-06-01)

Comparative Evaluation of Efficacy, Safety and Haemostatic Parameters of Enoxaparin and Fondaparinux in Unstable Coronary Artery Disease
by: Sanjay Shah, et al.
Published: (2014-01-01)

Old and New anticoagulants: The beginning of a new era?
by: Fidel Cáceres Loriga, et al.
Published: (2011-01-01)

Successful use of fondaparinux for perioperative bridging in a patient with a mechanical heart valve and heparin-induced thrombocytopenia
by: C R Pruthvi, et al.
Published: (2019-01-01)

Retrospective Analysis of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Women With Recurrent Spontaneous Abortion
by: Long Zhao, et al.
Published: (2021-10-01)

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
by: Cardillo G, et al.
Published: (2021-02-01)

The Challenging Anticoagulant Therapy in COVID19 Patient with Associated Coagulopathy
by: Raissa Virgy Rianda, et al.
Published: (2021-07-01)

ANTICOAGULANTS IN ACUTE CORONARY SYNDROME
by: I. A. Latfullin, et al.
Published: (2016-01-01)

Does ‘heparin-induced thrombocytopenia’ hit our minds?
by: Arun R. Thangavel, et al.
Published: (2016-08-01)

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
by: Vincenzo Russo, et al.
Published: (2020-11-01)

Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis
by: Kušić Jovana, et al.
Published: (2016-01-01)

Osteoporosis and antithrombotic therapy
by: N. V. Brailova, et al.
Published: (2021-06-01)

Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol
by: Dania Ghaziri, et al.
Published: (2023-01-01)

THE USE OF ENOXAPARIN IN ACUTE CORONARY SYNDROME
by: E. A. Smirnova, et al.
Published: (2017-01-01)

Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
by: Michelangelo Sartori, et al.
Published: (2020-10-01)

Monitoring strategies for patients treated with the new oral anticoagulants and the need for laboratory evaluation of hemostasis
by: Andrea Fontanella, et al.
Published: (2013-12-01)

Influence of fondaparinux versus nadroparin calcium thromboprophylaxis on clinical parameters following total knee arthroplasty
by: Zdravka Mihaljević, et al.
Published: (2016-01-01)

Fondaparinux
by: G. Airoldi, et al.
Published: (2013-05-01)

Use of fondaparinux in patients with heparin-induced thrombocytopenia on veno-venous extracorporeal membrane oxygenation: A three-patient case series report
by: Jitka Rychlíčková, et al.
Published: (2023-02-01)

ANTITHROMBOTIC THERAPY IN CANCER PATIENTS
by: A. V. Vorobev, et al.
Published: (2016-06-01)

Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer
by: Egidio Imbalzano, et al.
Published: (2021-12-01)

Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India
by: Saumitra Ray, et al.
Published: (2023-04-01)

Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis
by: Pravesh Kumar Bundhun, et al.
Published: (2017-05-01)

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis
by: Arun Kumar, et al.
Published: (2019-05-01)

In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments
by: Di Micco P, et al.
Published: (2020-06-01)

Management of Antithrombotic Agents in Oral Surgery Maria Martinez and Dimitrios A. Tsakiris *
by: Maria Martinez, et al.
Published: (2015-10-01)

Thrombotic Disorders and Antithrombotic Treatments Special Issue
by: Pierpaolo Di Micco
Published: (2022-02-01)

Updates in Anticoagulation Therapy Monitoring
by: Hannah L. McRae, et al.
Published: (2021-03-01)

Pharmacological properties of hirudin and its derivatives : potential clinical advantages over heparin /
by: 422288 Monreal, Manuel, et al.

Bivalirudin for cardiac catheterization in a pediatric patient with religious objection to the use of porcine-derived heparin
by: A. Caskey, et al.
Published: (2021-08-01)

FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME
by: G. V. Mardaryan, et al.
Published: (2015-09-01)

Cutaneous reactions to heparin therapy: when are they caused by heparin allergy?
by: Giuliana Zisa, et al.
Published: (2013-03-01)

Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study
by: Tianxiang Yang, et al.
Published: (2023-07-01)

Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study
by: Donglin Fu, et al.
Published: (2022-06-01)

A Literature Review of Pathophysiology, Clinical Manifestations, Medications and Optimal Dosage, Outpatient, and Post-hospitalization Use of Anticoagulation in COVID-19 Patients
by: Dimitrios Velissaris, et al.
Published: (2023-04-01)